Web-Based Phenotyping for Pharmacogenomics Research

K.E. Barnholt1, A.K. Kiefer1, T.K. Acquaye1, R.B. Altman2, H.L. McLeod3, J.A. Johnson4, C.B. Marsh5, J.Y. Tung1, J.L. Mountain1,

123andMe, Inc, Mountain View, CA; 2Department of Bioengineering, Stanford University, Stanford, CA; 3UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC; 4Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL; 5Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Internal Medicine, Ohio State University, Columbus, OH

Introduction

Significant barriers to the progress of pharmacogenomics research include the cost and time required to assemble, phenotype, and genotype an appropriately-sized cohort. 23andMe’s research program uses web-based surveys to gather a broad range of phenotype data from an expanding cohort of genotyped individuals. The primary goal of this study is to develop, assess, and implement web-based surveys for the rapid, efficient collection of drug response and toxicity data across three classes of medication: warfarin, proton pump inhibitors (PPIs), and non-steroidal anti-inflammatory drugs (NSAIDs). Results and conclusions presented here are from the initial phase of a two-part study.

Methods

Phase I: To develop valid questions on drug response and side effects, we conducted online and semi-structured phone interviews to assess test-retest reliability and to receive qualitative feedback on survey questions.

• Consenting customers who gave prior indication of warfarin or NSAIDs use were sent link to online survey
• Option to participate in a follow up phone interview was presented at end of online survey
• Warfarin: 86 people took initial web-based survey, 41 of them completed follow up phone interview
• NSAIDs: 107 people took initial web-based survey, 40 of them completed follow up phone interview
• Scored identical web-based and phone responses as a "match" and different answers between each method as a "mismatch"
• Calculated percent agreement between the 41 (warfarin) and 40 (NSAIDs) web-based and phone responses for each question

Results

• Agreement about warfarin specifics (dosage and frequency of administration) higher for current medications (86% matching) than for past regular use (71% matching)
• Strong overall agreement between web and phone responses for side effects reported by past and current warfarin users (89% for both)

NSAIDs Results Summary:

• Strong agreement between web and phone responses for side effects from current NSAIDs use (92% matching) and side effects reported for NSAIDs stopped some time in the past (94% matching)
• Test-retest reliability for relevant NSAIDs use was good, but reliability for past NSAIDs use was poor
• Efficacy data for improvement of inflammation and pain symptoms showed reasonable agreement, but a larger sample size is needed before making any conclusions

Phase I Conclusions

• Web-based surveys performed well in terms of getting medication response and side effects information
• Test-retest reliability for most questions was high (>70%)
• Reporting for past medications and medications taken as needed proved less reliable than for prescription medications (as expected)
• Low rates of agreement for some questions with commonly experienced symptoms may have stemmed from confusion about whether or not to mention symptoms unrelated to the medication
• Providing accurate date and dosage information often presented a challenge for many people
• Data were more reliable when questions focused on most recent use of the counter drugs that may be taken for multiple indications (i.e. NSAIDs)
• Online surveys must clarify potentially ambiguous terms (i.e. "regular use", "frequently", and "current")
• Increased reports of side effects over the phone may be due to additional familiarity with questions (all phone interviews followed completion of web-based surveys) and the fact that participants could ask for additional clarification during the interview

Future Plans

Phase II: To leverage 23andMe’s customized genotyping chip and incorporate data from tens of thousands of customers to validate known genetic associations (PPIs and CYP2C19: warfarin/NSAIDs and CYP2C9), and to search for novel associations of SNPs with drug efficacy and toxicity.

Based on findings and participant feedback from Phase I:

• Revise warfarin and NSAIDs surveys to re-release to larger subset (up to tens of thousands) of 23andMe customers
• Draft initial PPIs survey and send link to small subset of 23andMe customers for Phase I web and phone response comparisons

Since web-based surveys can be administered efficiently to millions of individuals, validation of this method of assessing drug response would remove traditional cost and time barriers and lead to significant acceleration of pharmacogenomics research.

Acknowledgments

We thank 23andMe’s customers who consented to participate in research for enabling this study. We also thank the employees of 23andMe who contributed to the development of the infrastructure that makes this research possible. This study is funded in part by NIH grant 1R44HG005807-01. RBA funded by GM61374.

References


